Skip to main
ESPR
ESPR logo

Esperion Therapeutics (ESPR) Stock Forecast & Price Target

Esperion Therapeutics (ESPR) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 19%
Hold 52%
Sell 5%
Strong Sell 0%

Bulls say

Esperion Therapeutics Inc is experiencing significant financial growth, as evidenced by a 53% increase in product revenue to $31.1 million for the latest quarter, driven by both retail prescription growth of 12% from the previous quarter and a remarkable 44% increase from the same quarter last year. In addition, the company benefits from strong marketing support from partner Daiichi Sankyo Europe, contributing to a 19% sequential rise in royalty revenues, indicating a robust demand for their products NILEMDO and NUSTENDI. Furthermore, the expansion of preferred commercial and Medicare coverage to over 92% and 65%, respectively, reinforces the expected positive sales trajectory and positions the company well for sustained long-term growth in the pharmaceutical market.

Bears say

Esperion Therapeutics Inc. has faced challenges in establishing a consistent path to profitability, reflected in its history of operating losses and incremental reductions in sales estimates for the current year. The company is at risk from potential competition, as breakthrough therapies may render its existing products obsolete, posing a significant threat to its future viability. Additionally, the recent changes in healthcare management of LDL-C levels, influenced by CLEAR Outcomes data, may further complicate Esperion's market position and financial outlook.

Esperion Therapeutics (ESPR) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 19% recommend Buy, 52% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Esperion Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Esperion Therapeutics (ESPR) Forecast

Analysts have given Esperion Therapeutics (ESPR) a Buy based on their latest research and market trends.

According to 21 analysts, Esperion Therapeutics (ESPR) has a Buy consensus rating as of Aug 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Esperion Therapeutics (ESPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.